BriaCell Therapeutics Competitors

BriaCell Therapeutics (NASDAQ:BCTX) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares BriaCell Therapeutics and AbCellera Biologics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BriaCell Therapeutics and AbCellera Biologics, as reported by MarketBeat.

AbCellera Biologics has a consensus target price of $52.80, suggesting a potential upside of 90.27%. Given AbCellera Biologics' higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than BriaCell Therapeutics.

Valuation and Earnings

This table compares BriaCell Therapeutics and AbCellera Biologics' revenue, earnings per share and valuation.

Summary

AbCellera Biologics beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and BriaCell Therapeutics (NASDAQ:BCTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Profitability

This table compares Abcam and BriaCell Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings for Abcam and BriaCell Therapeutics, as reported by MarketBeat.

Abcam presently has a consensus target price of $22.00, indicating a potential upside of 9.13%. Given Abcam's higher probable upside, equities research analysts plainly believe Abcam is more favorable than BriaCell Therapeutics.

Valuation and Earnings

This table compares Abcam and BriaCell Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Summary

Abcam beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

BriaCell Therapeutics (NASDAQ:BCTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BriaCell Therapeutics and Sana Biotechnology, as provided by MarketBeat.

Sana Biotechnology has a consensus target price of $40.00, suggesting a potential upside of 72.56%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than BriaCell Therapeutics.

Valuation & Earnings

This table compares BriaCell Therapeutics and Sana Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares BriaCell Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Summary

Sana Biotechnology beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

Seer (NASDAQ:SEER) and BriaCell Therapeutics (NASDAQ:BCTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Seer and BriaCell Therapeutics, as reported by MarketBeat.com.

Seer presently has a consensus target price of $68.00, indicating a potential upside of 40.76%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than BriaCell Therapeutics.

Valuation and Earnings

This table compares Seer and BriaCell Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Seer and BriaCell Therapeutics' net margins, return on equity and return on assets.

Summary

Seer beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

BriaCell Therapeutics (NASDAQ:BCTX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for BriaCell Therapeutics and Nuvation Bio, as reported by MarketBeat.com.

Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 69.92%. Given Nuvation Bio's higher possible upside, analysts plainly believe Nuvation Bio is more favorable than BriaCell Therapeutics.

Profitability

This table compares BriaCell Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares BriaCell Therapeutics and Nuvation Bio's revenue, earnings per share and valuation.

Summary

Nuvation Bio beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and BriaCell Therapeutics (NASDAQ:BCTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares ImmunityBio and BriaCell Therapeutics' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ImmunityBio and BriaCell Therapeutics, as reported by MarketBeat.com.

ImmunityBio presently has a consensus target price of $25.00, indicating a potential upside of 50.15%. Given ImmunityBio's higher possible upside, equities research analysts plainly believe ImmunityBio is more favorable than BriaCell Therapeutics.

Profitability

This table compares ImmunityBio and BriaCell Therapeutics' net margins, return on equity and return on assets.

Summary

ImmunityBio beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.